Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Allergan plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Allergan plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Allergan plc (“Allergan” or the “Company”) (NYSE: AGN) and/or Actavis plc. Investors who purchased or otherwise acquired shares between February 25, 2014 and November 3, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the January 3, 2017 lead plaintiff motion deadline.

If you purchased shares of Allergan during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that Allergan made false and/or misleading statements and/or failed to disclose that: Allergan and Actavis engaged in conduct that would result in a Department of Justice (“DOJ”) antitrust investigation; that the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against the Company by the end of 2016 for suspected price collusion; that Allergan and Actavis lacked effective internal controls; and that as a result of the above, Allergan’s and Actavis’ public statements were materially false and misleading at all relevant times. When this information was disclosed to the public, shares of Allergan dropped in value, causing investors harm.

If you wish to learn more about this lawsuit at no charge to you, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today